Biogen, Eisai Alzheimer's candidate lecanemab linked to third patient death
ChrisChrisW/iStock via Getty Images


A third patient has died while taking Biogen (NASDAQ:BIIB) and Eisai's (OTCPK:ESALY) (OTCPK:ESALF) experimental Alzheimer's treatment lecanemab and the fatality is being linked to the drug, Science reported.
The journal said the death was in a 79-year-old woman who experienced extensive brain swelling and bleeding, as well as seizures.

This is not the first time brain swelling and bleeding has been observed with lecanemab. Brain hemorrhaging was seen in the other two trial deaths as well.

Science said that based on the woman's health records, she had early Alzheimer's and no obvious health problems.
The third death comes as the FDA is set to act on the lecanemab BLA by Jan. 6, 2023.
On Thursday, the Institute for Clinical and Economic Review (ICER) said that for lecanemab to be cost effective, it would need to be priced $9K-$21K per year.